



As published Monday, August 01, 2016

BARDA awards Altimune anthrax contract

Altimune Inc. (Gaithersburg, Md.) said HHS's Biomedical Advanced Research and Development Authority (BARDA) awarded it a contract for up to \$120.2 million to fund clinical development of anthrax vaccine candidate NasoShield (formerly AdVAV anthrax vaccine).

The five-year contract provides \$14.3 million to fund a Phase I trial of NasoShield that is scheduled to begin in 2H17, with options for an additional \$105.9 million that would fund further development.

NasoShield is an intranasal recombinant protein antigen (rPA)-based vaccine. Altimune formerly was known as Vaxin Inc.